Basis (nicotinamide riboside/pterostilbene) / Elysium Health - LARVOL DELTA

Structural basis of lactate dehydrogenase A-gossypol complex. (PubMed, Biochem Biophys Res Commun) - "The binding of gossypol affects LDHA activity by a conformational change in the active-site loop. Our research contributes to the structural insight into LDHA with gossypol and approaches gossypol as a novel therapeutic candidate targeting the metabolic pathways for cancer cells."

Journal • Oncology • LDHA

Inhibition of UVB radiation-induced tissue swelling and immune suppression by nicotinamide riboside and pterostilbene. (PubMed, Photodermatol Photoimmunol Photomed) - "Nicotinamide riboside and pterostilbene have protective effects against UVB radiation-induced tissue swelling and immune suppression."

Journal • Contact Dermatitis • Immunology • Inflammation • Oncology • Skin Cancer

Protection From Acute Kidney Injury (AKI) With Basis™ Treatment (clinicaltrials.gov) - P2 | N=54 | Completed | Sponsor: Mayo Clinic | Active, not recruiting ➔ Completed | N=238 ➔ 54

Enrollment change • Trial completion • Acute Kidney Injury • Cardiovascular • Nephrology • Renal Disease

Protection From Acute Kidney Injury (AKI) With Basis™ Treatment (clinicaltrials.gov) - P2 | N=238 | Active, not recruiting | Sponsor: Mayo Clinic | Recruiting ➔ Active, not recruiting | Trial completion date: Oct 2023 ➔ Mar 2024 | Trial primary completion date: Oct 2023 ➔ Mar 2024

Enrollment closed • Trial completion date • Trial primary completion date • Acute Kidney Injury • Cardiovascular • Nephrology • Renal Disease

A Trial of Nicotinamide/Pterostilbene Supplement in ALS: The NO-ALS Extension Study (clinicaltrials.gov) - P=N/A | N=300 | Recruiting | Sponsor: Haukeland University Hospital | Trial completion date: Oct 2023 ➔ Dec 2026 | Trial primary completion date: Oct 2023 ➔ Dec 2025

Trial completion date • Trial primary completion date • Amyotrophic Lateral Sclerosis • CNS Disorders

Nicotinamide riboside, pterostilbene and ibudilast protect motor neurons and extend survival in ALS mice. (PubMed, Neurotherapeutics) - "Nicotinamide riboside (a NAD precursor) and pterostilbene (a natural antioxidant) were efficacious in a human pilot study of ALS patients and in ALS SOD1 transgenic mice...In conclusion, our results show that the combination of nicotinamide riboside, pterostilbene and ibudilast improve neuromotor functions and survival in ALS murine models. Studies on the underlying mechanisms show that motor neuron protection involves the decrease of oxidative and nitrosative stress, the combination of which is highly damaging to motor neurons."

Journal • Preclinical • Amyotrophic Lateral Sclerosis • CNS Disorders • Inflammation • FUS • IFNG • IL1B • MIF • TNFA

The NO-ALS Study: A Trial of Nicotinamide/Pterostilbene Supplement in ALS. (clinicaltrials.gov) - P=N/A | N=380 | Recruiting | Sponsor: Haukeland University Hospital | Trial completion date: Oct 2022 ➔ Aug 2025 | Trial primary completion date: Oct 2022 ➔ Aug 2025

Trial completion date • Trial primary completion date • Amyotrophic Lateral Sclerosis • CNS Disorders • NEFL

Protection From Acute Kidney Injury (AKI) With Basis™ Treatment (clinicaltrials.gov) - P2 | N=238 | Recruiting | Sponsor: Mayo Clinic | Trial completion date: Dec 2024 ➔ Oct 2023

Trial completion date • Acute Kidney Injury • Cardiovascular • Nephrology • Renal Disease • IGFBP7 • KIM1 • TIMP2

NRPT reduces markers of hepatic inflammation in non-alcoholic fatty liver disease: a double-blind, placebo-controlled clinical trial. (PubMed, Hepatology) - "This study demonstrates that NRPT at the recommended dose is safe and may hold promise in lowering markers of hepatic inflammation in patients with NAFLD."

Clinical • Journal • Addiction (Opioid and Alcohol) • Hepatology • Immunology • Inflammation • Non-alcoholic Fatty Liver Disease

A randomized placebo-controlled trial of nicotinamide riboside+pterostilbene supplementation in experimental muscle injury in elderly subjects. (PubMed, JCI Insight) - P=N/A | "Daily supplementation with 1000 mg NR+200 mg PT is safe but does not improve recruitment of the MuSC pool or other measures of muscle recovery in response to injury or subsequent regeneration in elderly subjects."

Journal • Musculoskeletal Pain • MB

Gene expression profiles in sporadic ALS fibroblasts define disease subtypes and the metabolic effects of the investigational drug EH301. (PubMed, Hum Mol Genet) - "A subset of genes differentially expressed in sALS fibroblasts was used in a machine learning model to predict disease progression. In conclusion, multi-omics analyses highlighted differential metabolic and transcriptomic profiles in patient-derived fibroblast sALS, which translate into differential responses to the investigational drug EH301."

Journal

Effects of a Seven-day BASIS™ Supplementation on Menopausal Syndromes and Measurements of the Urinary Vitamin B3 and Estradiol Levels in Pre-, Peri- and Post-menopause (clinicaltrials.gov) - P=N/A; N=40; Completed; Sponsor: University of South Alabama; Recruiting ➔ Completed; Trial completion date: Oct 2021 ➔ Jul 2021

Trial completion • Trial completion date

A Trial of Nicotinamide/Pterostilbene Supplement in ALS: The NO-ALS Extension Study (clinicaltrials.gov) - P=N/A; N=300; Recruiting; Sponsor: Haukeland University Hospital

Clinical • New trial • Amyotrophic Lateral Sclerosis • CNS Disorders

The NO-ALS Study: A Trial of Nicotinamide/Pterostilbene Supplement in ALS. (clinicaltrials.gov) - P=N/A; N=380; Recruiting; Sponsor: Haukeland University Hospital; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Amyotrophic Lateral Sclerosis • CNS Disorders • Complement-mediated Rare Disorders

The NO-ALS Study: A Trial of Nicotinamide/Pterostilbene Supplement in ALS. (clinicaltrials.gov) - P=N/A; N=380; Not yet recruiting; Sponsor: Haukeland University Hospital

Clinical • New trial • Amyotrophic Lateral Sclerosis • CNS Disorders • Complement-mediated Rare Disorders

Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study. (PubMed, Amyotroph Lateral Scler Frontotemporal Degener) - "This study provides evidence in support of the disease-modifying effects of EH301 for the treatment of ALS."

Clinical • Journal